Morgan Stanley analyst Tejas Savant lowered the firm’s price target on Veracyte (VCYT) to $28 from $29 and keeps an Underweight rating on the shares. The company reported a solid Q2 beat on continued Decipher/Afirma momentum leading to a 2025 guidance raise, the analyst tells investors in a research note. The firm added that Veracyte’s pipeline is promising an represents substantial opportunity, though meaningful upside remains a 2027+ dynamic.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCYT:
- Veracyte’s Strong Clinical Evidence and Market Growth Justify Buy Rating
- Veracyte Inc’s Earnings Call Highlights Robust Growth and Strategic Milestones
- Veracyte’s Strong Financial Performance and Promising Growth Prospects Justify Buy Rating
- Veracyte’s Strong Financial Performance and Growth Prospects Justify Buy Rating
- Veracyte Reports Strong Q2 2025 Revenue Growth